We cannot ignore that. We should not randomly categorize as bad actors those who have done what this committee has, frankly, encouraged them to do, investing in cutting-edge therapies like gene editing and regenerative medicine, because their list price is over an arbitrary amount.
Michael Burgess: “We cannot ignore that. We should not randomly categorize as bad actors those who have done what this committee has…”
Editor's note · Context
Advocates against labeling innovative drug developers as bad actors due to high prices.
Share
More from Michael Burgess
For the purpose of debate only, I yield the customary 30 minutes to the Congresswoman from Pennsylvania (Ms. Scanlon), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is…
I will simply underscore the fact that entry- level chemists at the EPA are hired at much higher than the GSA rate. These are not highly sought-after scientists. These are entry-level applicants, and there is no shortage of applicants for…
I led a letter to the FDA asking them to reclassify naloxone to where you could get it without a prescription.
I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.





